ESR1 and breast cancer: We used MBC2 and MBC26 PDXs to test the effect of WDR5 inhibition on lethality in combination with paclitaxel (PTX), indicated for first-line therapy in TN breast cancer and later-line therapy in ER+ metastatic breast cancer [49].